| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
Cortodoxone targets the glucocorticoid receptor, exhibiting glucocorticoid and anti-inflammatory activities. As a 17-hydroxycorticosteroid, it binds to and activates the glucocorticoid receptor, modulating the transcription of glucocorticoid-responsive genes involved in inflammation, immune responses, and various metabolic processes. Cortodoxone also has antiandrogenic properties, making it useful in the treatment of androgen-dependent conditions such as acne and scalp hair loss. It serves as a precursor to cortisol, the primary endogenous glucocorticoid. |
|---|---|
| ln Vitro |
In vitro, cortodoxone exhibits glucocorticoid and anti-inflammatory activities. It binds to the glucocorticoid receptor and modulates the expression of glucocorticoid-responsive genes. As a precursor to cortisol, it can be converted to the active glucocorticoid by 11β-hydroxylase in appropriate cellular contexts. The compound's antiandrogenic activity has been demonstrated in relevant cell-based assays. Cortodoxone is typically assessed in reporter gene assays using glucocorticoid response element (GRE)-luciferase constructs and in anti-inflammatory assays measuring cytokine production in immune cells. Its activity is compared to that of cortisol and other glucocorticoids.
|
| ln Vivo |
In vivo, cortodoxone functions as a precursor in the biosynthesis of cortisol, the primary endogenous glucocorticoid. It is converted to cortisol by the cytochrome P450 enzyme CYP11B1 (11β-hydroxylase). Cortodoxone has been used topically as an antiandrogen for the treatment of acne and is being developed for androgen-dependent scalp hair loss. Its topical application allows for localized effects with reduced systemic exposure. The compound's in vivo effects are mediated both through its own glucocorticoid activity and through its conversion to cortisol. Further clinical studies are needed to fully characterize its efficacy and safety profile.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for cortodoxone typically involve competitive binding experiments using glucocorticoid receptor and radiolabeled or fluorescently labeled dexamethasone as tracer. The compound's binding affinity to the glucocorticoid receptor is assessed, with IC₅₀ or Kd values determined. Assays are conducted in buffered solutions at physiological pH with appropriate receptor preparations. The compound's ability to activate glucocorticoid receptor-mediated transcription is evaluated using reporter gene assays with GRE-luciferase constructs. Its antiandrogenic activity can be assessed using androgen receptor binding assays.
|
| Cell Assay |
In vitro cell-based assays for cortodoxone utilize cell lines expressing glucocorticoid receptor to assess its glucocorticoid activity and anti-inflammatory effects. Cells are treated with varying concentrations of the compound for 24-48 hours. Glucocorticoid receptor-mediated transcriptional activity is evaluated using reporter gene assays with GRE-luciferase constructs. Anti-inflammatory activity is assessed by measuring the production of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β in immune cells following stimulation. Antiandrogenic activity can be evaluated in androgen-responsive cell lines. Standard cell culture conditions (37°C, 5% CO₂) with appropriate media are employed.
|
| Animal Protocol |
In vivo animal studies with cortodoxone typically involve topical or systemic administration to evaluate its glucocorticoid and antiandrogenic effects. Topical application studies may use models of skin inflammation or androgen-dependent conditions such as acne or hair loss. Endpoints include measurements of inflammation markers, assessment of skin condition, and evaluation of hair growth. Systemic administration studies may evaluate the compound's effects on glucose metabolism, immune function, and adrenal axis regulation. All procedures must comply with institutional animal care and use guidelines. Detailed published protocols are available in the literature.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
17β-21-dihydroxyprogesterone is a known human metabolite of 17α-hydroxyprogesterone. Cortodoxone has a molecular weight of 346.47 g/mol and a molecular formula of C₂₁H₃₀O₄. It is a precursor in cortisol biosynthesis and is converted to cortisol by CYP11B1 (11β-hydroxylase). The compound is used topically as an antiandrogen for acne treatment. Its pharmacokinetic properties when administered topically include limited systemic absorption, allowing for localized effects with reduced systemic side effects. The compound is also used as a pharmaceutical analytical impurity standard. Further pharmacokinetic studies are needed to fully characterize its absorption, distribution, metabolism, and excretion. |
| Toxicity/Toxicokinetics |
Cortodoxone has been used as an antiandrogen drug for topical treatment of acne and is being developed for androgen-dependent scalp hair loss. As a pharmaceutical agent, it has undergone toxicological evaluation for these indications. Common adverse effects associated with topical corticosteroid use may include skin irritation, thinning of the skin, and local immunosuppression. Systemic effects are limited due to low systemic absorption with topical administration. The compound should not be used in individuals with known hypersensitivity to corticosteroids or with certain skin infections. Comprehensive safety data are available from clinical use and development programs.
|
| References | |
| Additional Infomation |
11-Deoxycortisol is a deoxycorticol in which the 11-hydroxyl group is replaced by a hydrogen atom. It is a metabolite in both mice and humans. It is a glucocorticoid, and also a primary α-hydroxy ketone, tertiary α-hydroxy ketone, and deoxycortisol. Cortexolone is a metabolite found or produced in Escherichia coli (K12 strain, MG1655 strain). Human cortodoxone has been reported, and relevant data are available. Cortexolone is a glucocorticoid and an intermediate in the biosynthesis of adrenal cortisol. 17,21-Dihydroxypregn-4-ene-3,20-dione is a 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities.
Cortodoxone (CAS#: 152-58-9) has a molecular formula of C₂₁H₃₀O₄ and a molecular weight of 346.47 g/mol. Its synonyms include 11-deoxycortisol, cortexolone, and Reichstein's substance S. It is a 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities. Cortodoxone is a precursor in cortisol biosynthesis and is converted to cortisol by CYP11B1 (11β-hydroxylase). It is used topically as an antiandrogen for acne treatment and is being developed for androgen-dependent scalp hair loss. It is also used as a pharmaceutical analytical impurity standard. |
| Molecular Formula |
C21H30O4
|
|---|---|
| Molecular Weight |
346.46
|
| Exact Mass |
346.214
|
| CAS # |
152-58-9
|
| Related CAS # |
Cortodoxone-d5;1258063-56-7;Cortodoxone-d2;1271728-08-5
|
| PubChem CID |
440707
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
524.5±50.0 °C at 760 mmHg
|
| Melting Point |
215 °C
|
| Flash Point |
285.1±26.6 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.578
|
| LogP |
2.74
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
652
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C
|
| InChi Key |
WHBHBVVOGNECLV-OBQKJFGGSA-N
|
| InChi Code |
InChI=1S/C21H30O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h11,15-17,22,25H,3-10,12H2,1-2H3/t15-,16+,17+,19+,20+,21+/m1/s1
|
| Chemical Name |
(8R,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (144.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8863 mL | 14.4317 mL | 28.8634 mL | |
| 5 mM | 0.5773 mL | 2.8863 mL | 5.7727 mL | |
| 10 mM | 0.2886 mL | 1.4432 mL | 2.8863 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
